COMPOSITION AND METHODS FOR PREVENTING RADIATION INJURY AND PROMOTING TISSUE REGENERATION
Provided herein are compositions and methods for use in treating or preventing radiation injury in a subject at risk of such injury.
1 . A method of treating or preventing radiation injury in a subject at risk of such injury, comprising administering to the subject a composition comprising an isolated polypeptide comprising the carboxy terminal-most 4 to 30 contiguous amino acids of an alpha Connexin.
2 . The method of claim 1 , wherein the composition is administered prior to exposure of the subject to radiation.
3 . The method of claim 1 , wherein the composition is administered to the subject following exposure to radiation, wherein the method inhibits the progression of the radiation injury.
4 . The method of claim 1 , wherein the composition is administered topically to the subject.
5 . The method of claim 1 , wherein the composition further comprises hydroxyethylcellulose gel.
6 . The method of claim 5 , wherein the hydroxyethylcellulose gel is present at a concentration of about 1.25% (w/w).
7 . The method of claim 1 , wherein the composition is administered to the subject parenterally.
8 . The method of claim 7 , wherein the composition is administered to the subject by an intravenous, subcutaneous, intraperitoneal, intramuscular route.
9 . The method of claim 1 , wherein the composition is administered to the subject by aerosolized delivery.
10 . The method of claim 1 , wherein the composition is administered to the subject at a dose of from about 10 μM to about 2000 μM.
11 . The method of claim 1 , wherein the composition is administered to the subject at a dose of from about 100 μM to about 200 μM.
12 . The method of claim 1 , wherein the composition is administered to the subject at a dose of about 1 mg/kg to about 50 mg/kg.
13 . The method of claim 1 , wherein the subject is administered a composition comprising the polypeptide topically and is administered a compositon comprising the polypeptide systemically.
14 . The method of claim 1 , wherein the radiation injury is selected from the group consisting of cutaneous radiation injury (CRI), acute radiation syndrome (ARS), combined radiation injury, radiation burns, radiation dermatitis, radiation injury to the nervous system or brain, radiation pneumonitis, radiation-induced enteritis, or a combination thereof.
15 . The method of claim 14 , wherein the radiation injury comprises CRT and ARS.
16 . The method of claim 14 , wherein the radiation dermatitis is a result of a medical intervention.
17 . The method of claim 16 , wherein the medical intervention is a cancer therapy.
18 . The method of claim 17 , wherein the cancer therapy is radiotherapy.
19 . The method of claim 1 , wherein the radiation injury results from exposure to a source of radiation selected from the group consisting of weapons of mass destruction (WMD), nuclear explosions, and dirty bombs.
20 . The method of claim 19 , wherein the radiation injury results from exposure to a dirty bomb.
21 . The method of claim 1 , wherein the radiation injury results from exposure to a source of radiation selected from the group consisting of a diagnostic machine, the sun, or a tanning bed.
22 . The method of claim 1 , wherein the radiation injury occurs in a tissue selected from the group consisting of skin, heart, bone, brain, spinal cord, cornea, retina, and peripheral nerve.
23 . The method of claim 22 , wherein the radiation injury occurs on the skin.
24 . The method of claim 19 , wherein the average skin score is decreased by at least about 30% in presence of the polypeptide as compared to a control.
25 . The method of claim 1 , wherein the polypeptide prevents uptake of radionuclides.
26 . The method of claim 1 , wherein the polypeptide consists of the carboxy terminal-most 5 to 19 contiguous amino acids of the alpha Connexin.
27 . The method of claim 1 , wherein the alpha Connexin is Connexin 37, Connexin 40, Connexin 43, or Connexin 45.
28 . The method of claim 1 , wherein the polypeptide comprises the amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, and SEQ ID NO: 5.
29 . The method of claim 28 , wherein the polypeptide comprises the amino sequence of SEQ ID NO: 2.
30 . The method of claim 1 , wherein the polypeptide further comprises a cellular internalization sequence.
31 . The method of claim 30 , wherein the cellular internalization sequence comprises an amino acid sequence of a protein selected from a group consisting of Antennapedia, TAT, HIV-Tat, Penetratin, Antp-3A (Antp mutant), Buforin II, Transportan, MAP (model amphipathic peptide), K-FGF, Ku70, Prion, pVEC, Pep-1, SynB 1, Pep-7, HN-1, BGSC (Bis-Guanidinium-Spermidine-Cholesterol) and BGTC (Bis-Guanidinium-Tren-Cholesterol).
32 . The method of claim 31 , wherein the cellular internalization sequence is Antennapedia, and wherein the sequence comprises the amino acid sequence of SEQ ID NO:7.
33 . The method of claim 1 , wherein the polypeptide comprises the amino acid sequence selected from the group consisting of SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1, and SEQ ID NO:12.
34 . The method of claim 33 , wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:9.
35 . The method of claim 1 , wherein the composition comprises SEQ ID NO: 91.
36 . A method of preventing radiation injury in a subject at risk of such injury, comprising administering to the subject a composition comprising an isolated polypeptide comprising the carboxy terminal-most 4 to 30 contiguous amino acids of an alpha Connexin.